THE 5-SECOND TRICK FOR TRASTUZUMAB ANNS

Among the most under-investigated “driving forces” involved in trastuzumab resistance is PTEN. Nagata et al. (2004) documented the loss of PTEN was noticed in 36% of HER2-constructive primary breast tumor specimens from patients with stage IV disorder. Additionally, Additionally they showed that people with PTEN-deficient tumors had remarkably